Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.65 |
| ▸ | CES1 | P23141 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954392 | 0.89 | CES2 (0.68) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL23421455 | 0.88 | CES2 (0.57) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL5651058 | 0.88 | CES2 (0.52) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL8359445 | 0.87 | CES2 (0.65) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL28305665 | 0.85 | ALDH1A1 (0.49) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL523258 | 0.83 | CES2 (0.61) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL14012584 | 0.83 | CES2 (0.61) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL20551726 | 0.83 | CES2 (0.61) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL6968044 | 0.83 | CES2 (0.61) | CES2CES1RAB9AL3MBTL1MAPT | |
| SCHEMBL24779498 | 0.83 | CES2 (0.61) | CES2CES1RAB9AL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| US-4255594-A | Hydrogenation of halogen-containing carboxylic anhydrides | ALLIED CHEMICAL CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |